Exclusive: OpenLoop has acquired Season Health OpenLoop Health, a startup powering telehealth companies, has acquired food-as-medicine startup Season Health, OpenLoop confirmed to Endpoints News.

Exclusive: OpenLoop has acquired Season Health

The tide is starting to turn in pharma's favor for the future of 340B Drugmakers and the federal government have historically been on opposing sides of contract pharmacy policy under 340B. But in two cases against state laws, they’ve become unexpected allies.

Momentum may be shifting in pharma’s favor on 340B, as the federal government backs drugmakers in key cases challenging state discount laws.

Novo claims that its obesity pill is better than Lilly’s. Only a head-to-head trial can prove it A day after Eli Lilly gained FDA approval for its obesity pill Foundayo, Novo Nordisk is fighting back with an analysis that it says shows the superiority of its own oral drug.

Novo Nordisk says its obesity pill outperforms Lilly’s, but the claim is based on cross-trial analysis — and only a head-to-head study can settle the debate.

A dog with cancer named Rosie ignites the latest debate between AI enthusiasts and biologists An Australian man has been on a two-year-long quest to save his dog from cancer. Its viral reception has led to debate in the AI biotech world.

A cancer-stricken dog named Rosie has become the center of a new AI debate, as her owner’s chatbot-designed treatment sparks both hype and skepticism across biotech.

Lilly's chief technology officer retires after 35 years; Astellas strategy exec resigns Tim Coleman has retired as chief technology officer at Eli Lilly, ending a 35-year career with the pharma giant in his hometown of Indianapolis.

In this week’s Peer Review: Eli Lilly’s CTO Tim Coleman retires after 35 years, Astellas’ strategy chief Adam Pearson steps down, and Bayer names Nelson Ambrogio as US pharma president.

Alto Neuroscience shelves schizophrenia cognitive impairment program after Phase 2 miss Alto Neuroscience said its PDE4 inhibitor failed a mid-stage trial in schizophrenia-related cognitive impairment, prompting the biotech to drop plans to advance the program on its own.

Alto Neuroscience is shelving its schizophrenia program after a Phase 2 miss, shifting focus to its lead depression candidate.

Trump is preparing 100% tariffs on some drugmakers, documents show President Donald Trump is reportedly set to implement 100% pharmaceutical tariffs as soon as Thursday although, according to a draft seen by Endpoints News, it appears it would only affect a small por...

⚡ Breaking: Trump's tariffs are coming but may only affect some drugmakers

Immunovant's FcRn drug fails in a pair of Phase 3 trials in thyroid eye disease Immunovant’s eye drug batoclimab failed in two late-stage trials in thyroid eye disease (TED), the company disclosed Thursday.

Immunovant’s FcRn drug batoclimab failed two Phase 3 trials in thyroid eye disease, raising questions about the program’s future as shares fell.

Oric to advance prostate cancer drug to Phase 3, but combo choice raises doubts Oric Pharmaceuticals on Tuesday detailed its plans to advance an PRC2 inhibitor into a registrational program for prostate cancer after sharing results from a Phase 1b trial.

Oric's prostate cancer drug earns its Phase 3 shot, but the combo choice draws scrutiny.
endpoints.news/oric-to-adva...

Exclusive: First clinical trial of tRNA therapy, a new disease-agnostic form of genetic medicine, will start soon Alltrna receives clearance for the first clinical trial of a tRNA-based therapy that could one day be used to treat multiple genetic diseases, starting with tests in Australia. The company raised $109...

Exclusive: A new class of genetic medicine is heading to the clinic, as Alltrna prepares to launch the first human trial of a reusable tRNA therapy.
endpoints.news/first-clinic...

Updated: Biogen highlights kidney disease ambitions in $5.6B Apellis buyout Biogen has made a $5.6 billion deal to acquire Apellis Pharmaceuticals, the companies announced Tuesday.

Biogen is acquiring Apellis for $5.6B, adding its kidney and eye disease drugs in a deal that caps a wave of mid-size biotech M&A and signals its next strategic move.

Live today: MAHA, vaccine politics and the risk for Republicans — with former Congressman Michael Burgess Former GOP Rep. Michael Burgess to discuss vaccine politics and Republican party split with Drew Armstrong and Max Bayer at 12:30 p.m. ET on YouTube.

Live today at 12:30 p.m. ET: Former Congressman Michael Burgess joins Post-Hoc Live to discuss MAHA, vaccine politics and the risks for Republicans. Join us live and set a reminder.

Eli Lilly to buy Centessa for $6.3B to get sleep disorder drug Eli Lilly is making its biggest acquisition in years, devoting part of its GLP-1 cash influx to buy Centessa Pharmaceuticals and its experimental medicines for sleep disorders and neurological conditi...

Eli Lilly is buying Centessa for $6.3B upfront to gain its sleep disorder drug, expanding into orexin biology as it looks beyond obesity.

White House overtures to pharma on new pricing talks met with frosty reception White House efforts to gain pharma industry support for drug pricing legislation face resistance, with some companies declining invitations to review draft text. AstraZeneca, Merck, Lilly, BMS met in ...

White House efforts for new drug pricing talks are hitting resistance, with some pharma companies declining to engage as officials push to codify last year’s deals.

Takeda cuts 600+ US jobs; United's stock rises on Tyvaso data Plus, news about Almirall, Biogen, Aurinia, Day One, Alamar and more.

Takeda sheds more than 600 US jobs; United Therapeutics gets a lift from fresh Tyvaso data.

Blackstone raises $6.3B life sciences fund in record fundraising haul Blackstone raises record $6.3B life sciences fund (Blackstone Life Sciences VI), marking largest-ever private investment fund in life sciences industry

Blackstone raises a record-breaking $6.3B for life sciences.
endpoints.news/blackstone-r...

Biogen declares Phase 2 lupus success for anti-BDCA2 antibody Biogen reports Phase 2 lupus drug litifilimab showed significant improvement in skin lesions vs placebo, with 14.7% of patients reaching clear/near-clear skin.

Biogen's anti-BDCA2 lupus antibody succeeds in Phase 2, giving the company a much-needed bit of optimism in its autoimmune efforts.
endpoints.news/aad26-biogen...

Sanofi reports underwhelming Phase 3 OX40 data in eczema, second case of Kaposi’s sarcoma Sanofi shares mixed Phase 3 data for amlitelimab in atopic dermatitis, with weaker efficacy vs Dupixent and a second Kaposi's sarcoma case reported at AAD meeting.

Sanofi's OX40L drug posts another unimpressive Phase 3 eczema result, deepening doubts.
endpoints.news/aad26-sanofi...

AnaptysBio spins out biotech operations; Affibody's data in hidradenitis suppurativa Zenas plans $300M offering via convertible notes and stock sale, while Ysios Capital launches €100M InceptionBio fund focusing on Spanish biotech investments

AnaptysBio spins out biotech operations; Affibody's data in hidradenitis suppurativa.
endpoints.news/anaptysbio-s...

After years of setbacks, FDA approves Rocket's gene therapy for ultra-rare immune disease FDA approves Rocket Pharma's gene therapy Kresladi for rare immune disorder LAD-I after earlier rejection, offering new treatment for babies & children without matched donors

After years of setbacks, FDA approves Rocket's gene therapy for ultra-rare immune disease.
endpoints.news/fda-approves...

AstraZeneca’s COPD antibody gets Phase 3 wins in broader-than-expected population AstraZeneca's tozorakimab succeeds in two Phase 3 COPD trials, showing efficacy in broad patient populations despite earlier Phase 2 failure. Data details pending.

AstraZeneca’s COPD antibody gets Phase 3 wins in broader-than-expected population.
endpoints.news/astrazenecas...

Novartis to spend up to $2B on Excellergy and its next-gen Xolair candidate Novartis to pay up to $2B for Excellergy and its IgE antibody Exl-111, as Xolair faces biosimilar competition. Drug in Phase 1 could treat food allergies and other conditions.

Novartis bets up to $2B that Excellergy's next-gen Xolair candidate can extend its food allergy franchise.
endpoints.news/novartis-to-...

Limbic aims to show AI beats humans in delivering therapy Study in Nature Medicine shows Limbic's AI therapy system outperformed human clinicians in CBT skills and matched their trust levels, based on 227-participant trial and 20,000 conversations

AI startup Limbic says its therapy model outperformed human clinicians in a Nature Medicine study, as it pushes to expand AI-driven mental health care.

Post-Hoc: It’s time to make ACIP serious again Who knows what’s going to happen to the Advisory Committee on Immunization Practices?

Post-Hoc: ACIP is in disarray, and US vaccine policy is stuck in limbo — it’s time to restore credibility to one of the country’s most important advisory panels.

Wave crashes on obesity disappointment Wave Life Sciences' obesity drug WVE-007 shows only 1% more weight loss than placebo in Phase 1 study, falling short of FDA's 5% threshold, causing stock to drop 55%

Wave Life Sciences’ obesity drug disappointed in early data, showing just 1% weight loss over placebo and sending shares down more than 55%.

The next oral peptide bet: Pinnacle Medicines gets $89M from US and China investors Pinnacle Medicines raises $89M Series B for oral peptides, including asthma/COPD drug and weight-loss pill, following Novo Nordisk's oral Wegovy success.

The pill version of Novo Nordisk’s blockbuster Wegovy showed what was possible when drug chemists turned peptides into oral molecules. Now investors have found their next related bet.
endpoints.news/oral-peptide...

Boehringer Ingelheim is leaning on dealmaking, obesity R&D and continued investment to offset US pricing pressure, including potential partnerships in China.

Beam looks to accelerated approval for AATD base editing after promising update Beam Therapeutics reports positive results from CRISPR base editing therapy for AATD, saying it is ready to seek accelerated approval for a moderate two-dose regimen.

Beam is aiming for accelerated approval of its AATD base editing therapy after new data showed strong correction of the disease-driving protein in early trials.

Gilgamesh's psychedelics pipeline gets $60M backing after AbbVie deal Gilgamesh Pharma raises $60M Series A to advance psychedelics pipeline, following $906M AbbVie deal last year. Plans Phase 3 for NMDA antagonist & Phase 1 for ibogaine analog.

The psychedelics field just got another vote of confidence: Gilgamesh raises $60M on the heels of its AbbVie deal.

Merck to buy Terns for $6.7B, taking a leukemia drug that could challenge Scemblix Merck to acquire Terns Pharmaceuticals, gaining TERN-701 for chronic myeloid leukemia treatment. Deal strengthens oncology pipeline ahead of Keytruda patent cliff.

With a $6.7B Terns deal, Merck puts a leukemia challenger to Scemblix squarely in its pipeline.
endpoints.news/merck-to-buy...